Drugs / ASD141
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06235437 | Aug 2024 → Dec 2026 expected | metastatic neoplasm | Ascendo Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASD141 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06235437 ↗ |
| Route | Intravenous | “IV, Monotherapy” NCT06235437 ↗ |